Read the experiment behind the verb.
Here are the papers and official documents behind the reading. Each link has a different job, and the setting matters.
A few details change what a paper can tell us.
These are the sources used on Metabolix Peptides. The setting matters: a mouse experiment, a human measurement and a treatment trial answer different questions.
Use
the study that fits the claim
A weight trial answers a weight question. A mouse fuel-use experiment answers something else. Check what was tested, not just the title.
Store
the setting beside the result
One paper can combine animal treatment experiments with measurements in people. Check which part supports the claim.
Respond
to the warnings as well as the benefits
Benefits and unwanted effects both matter. FDA documents explain approved uses or safety and access limits; a research finding cannot settle those alone.
The source has to support the sentence.
A link doesn’t rescue an overstatement. If our claim exceeds the paper, the wording needs another look. The contact page explains how to flag it.
The reading list
Semaglutide and weight change in adults
Wilding and colleagues, New England Journal of Medicine, 2021.The STEP 1 trial measured weight change in adults with overweight or obesity, without diabetes. It compared semaglutide with a dummy treatment.
AOD-9604 and fat use in mice
Heffernan and colleagues, Endocrinology, 2001.Mice bred without the beta-3 adrenergic receptor still used more fat after a dose, but lacked the weight response to repeated treatment seen in mice with that receptor.
How people tolerated AOD-9604 in trials
Stier, Vos and Kenley, Journal of Endocrinology and Metabolism, 2013.Reports human safety and tolerability findings. Oral obesity trials lasted no more than 24 weeks; their tolerability findings do not establish long-term or injection safety.
MOTS-c and fuel use in cells and mice
Lee and colleagues, Cell Metabolism, 2015.The discovery paper describes MOTS-c and its effects on fuel handling in cells and mice. It does not establish a human treatment benefit.
MOTS-c in exercise research
Reynolds and colleagues, Nature Communications, 2021.Combines treatment experiments in mice with measurements of the body’s own MOTS-c in people. The human participants were not given MOTS-c.
A review of semaglutide safety
Smits and Van Raalte, Frontiers in Endocrinology, 2021.Discusses unwanted effects, including digestive and gallbladder problems. Read safety findings alongside the trial benefits.
Semaglutide and heart outcomes
Lincoff and colleagues, New England Journal of Medicine, 2023.SELECT counted cardiovascular deaths, nonfatal heart attacks and nonfatal strokes together. It studied adults aged 45 or older with established heart or blood-vessel disease and overweight or obesity, without diabetes.
Wegovy’s U.S. prescribing information
U.S. Food and Drug Administration, June 2026 label.Sets out approved uses, warnings and situations where this medicine must not be used. Approval of Wegovy does not cover compounded semaglutide.
FDA’s withdrawn nominations and safety concerns
U.S. Food and Drug Administration, page current as of April 22, 2026.Lists AOD-9604 and MOTS-c among withdrawn nominations. FDA still describes safety concerns; withdrawal does not permit compounding.
FDA’s review of MOTS-c
FDA evaluation dated May 11, 2026, prepared for the July 23–24 advisory meeting.Found no human treatment or safety studies and raised concerns about immune reactions. This staff evaluation is not drug approval.
A registered human trial of MOTS-c
ClinicalTrials.gov trial record, checked in September 2026.Describes a study in adults with prediabetes and extra weight. No results were posted when the record was checked.